Bimagrumab
A Study of Bimagrumab (LY3985863) and Tirzepatide (LY3298176), Alone or in Combination, in Participants With Obesity or Overweight With Type 2 Diabetes
Eli Lilly · Phase 2 · Withdrawn · Enrollment 0
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Bimagrumab Dose 1 + Tirzepatide Placebo | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 2 + Tirzepatide Placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 1 + Bimagrumab Placebo | n/r | n/r | n/r | n/r |
| Tirzepatide Dose 2 + Bimagrumab Placebo | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 2 + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 1 + Tirzepatide Dose 1 | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 2 + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r |
| Bimagrumab Dose 1 + Tirzepatide Dose 2 | n/r | n/r | n/r | n/r |
| Bimagrumab Placebo + Tirzepatide Placebo | n/r | n/r | n/r | n/r |
Not shown
- Bimagrumab Dose 1 + Tirzepatide Placebo: endpoint not reported
- Bimagrumab Dose 2 + Tirzepatide Placebo: endpoint not reported
- Tirzepatide Dose 1 + Bimagrumab Placebo: endpoint not reported
- Tirzepatide Dose 2 + Bimagrumab Placebo: endpoint not reported
- Bimagrumab Dose 2 + Tirzepatide Dose 1: endpoint not reported
- Bimagrumab Dose 1 + Tirzepatide Dose 1: endpoint not reported
- Bimagrumab Dose 2 + Tirzepatide Dose 2: endpoint not reported
- Bimagrumab Dose 1 + Tirzepatide Dose 2: endpoint not reported
- Bimagrumab Placebo + Tirzepatide Placebo: endpoint not reported